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Abstract
Background: Over-activity and elevated expression of glycogen synthase kinase-3 (GSK-3) has been implicated in the
etiology of insulin resistance and Type 2 diabetes. Administration of specific GSK-3 inhibitors to diabetic or obese rodent
models improves glycaemic control and insulin sensitivity. However, due to the indiscriminatory nature of these inhibitors,
the relative contribution of the two isoforms of GSK-3 (GSK-3a and GSK-3b) is not known. Recently, we demonstrated that
an out-bred strain of mice (ICR) lacking expression of GSK-3a in all tissues displayed improved insulin sensitivity and
enhanced hepatic glucose metabolism. We also found that muscle (but not liver) inactivation of GSK-3b conferred insulin
and glucose sensitization in an in-bred strain of mice (C57BL/6).
Methodology/Principal Findings: Here, we have employed tissue-specific deletion of GSK-3a, to examine the relative
contribution of two insulin-sensitive tissues, muscle and liver, towards the insulin sensitization phenotype originally
observed in the global GSK-3a KO animals. We found that mice in which GSK-3a has been inactivated in either skeletal-
muscle or liver displayed no differences in glucose tolerance or insulin sensitivity compared to wild type littermates. Given
the strain differences in our original analyses, we examined the insulin and glucose sensitivity of global GSK-3a KO animals
bred onto a C57BL/6 background. These animals also revealed no significant differences in glucose metabolism/insulin
sensitivity compared to their wild type littermates. Furthermore, deletion of hepatic GSK-3a on the out-bred, ICR
background failed to reproduce the insulin sensitivity manifested by the global deletion of this isoform.
Conclusions/Significance: From these data we conclude that the improved insulin sensitivity and hepatic glucose
homeostasis phenotype observed upon global inactivation of GSK-3a is strain-specific. We surmise that the insulin-
sensitization observed in the out-bred strain of mice lacking GSK-3a is mediated by indirect means that do not require
intrinsic function of GSK-3a in skeletal muscle and liver tissues.
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Introduction
Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed
serine/threonine protein kinase that is encoded by two distinct
genes, GSK-3a (52 kDa) and GSK-3b (47 kDa). These two
isoforms are highly conserved and share ,98% sequence
similarity in their catalytic domains [1]. GSK-3 is a constitutively
active kinase in resting cells that becomes rapidly inactivated by
phosphorylation at Ser 21 (GSK-3a) and Ser 9 (GSK-3b)i n
response to insulin through a phosphatidylinositol 3 (PI-3) kinase/
protein kinase B (PKB, also termed Akt)-dependent manner.
Both GSK-3 expression and activity are elevated in muscle and
adipose tissue of diabetic humans and rodents [2,3]. In addition,
GSK-3 inhibitors improve insulin sensitivity in rodent models of
diabetes, alleviating hyperglycaemia by decreasing hepatic gluco-
neogenesis and stimulating glycogen synthesis [4,5,6]. Further-
more, novel peptide inhibitors of GSK-3 (L803-mts) reverse the
diabetic state associated with the ob/ob mouse model [7].
Interestingly, generation of mice expressing insulin-insensitive
mutants of GSK-3 (conversion of Ser 21 of GSK-3a and Ser 9 of
GSK-3b to alanine; S21A/S9A), does not result in a diabetic
phenotype [8].
While the two GSK-3 isoforms are structurally similar, they are
not functionally equivalent. Mice lacking GSK-3b expression die
during embryogenesis (E13.5-16.5) displaying severe liver apopto-
sis and heart patterning defects [9,10]. Conversely, GSK-3a
knockout (KO) animals are viable and fertile and exhibit enhanced
insulin sensitivity and glucose tolerance, accompanied by elevated
hepatic glycogen deposition [11]. Interestingly, although insulin-
stimulated PKB and GSK-3b phosphorylation was significantly
increased in livers of GSK-3a KO animals, muscle insulin
signaling was unaffected by the loss of GSK-3a. By contrast,
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improved glucose tolerance, enhanced muscle glycogen deposition
and insulin-stimulated GS activity [12]. However, mice harbour-
ing liver-specific inactivation of GSK-3b exhibited normal
metabolic characteristics [12]. Pancreatic deletion of the same
isoform alleviated hyperglycaemia in IRS-2 KO mice [13]. The
data from these studies support the idea that there are isoform and
tissue-specific roles for GSK-3 in the regulation of glucose
metabolism and insulin action, such that GSK-3a is the
predominant regulator of hepatic GS and glycogen synthesis
while GSK-3b has more prevalent role in these processes within
skeletal muscle and pancreatic islet tissue. However, it remains
unclear as to whether the anti-diabetic phenotype observed in
GSK-3a KO animals is a direct effect of GSK-3a loss in insulin-
sensitive tissues, such as the liver, or whether the insulin
sensitization is a consequence of the functional loss of GSK-3a
in other tissues. To address this question, we have engineered the
conditional mouse line from which the global GSK-3a KO was
developed, and here, describe the generation of skeletal muscle-
and liver-specific GSK-3a KO mouse models. Our analysis spans
several strains of mouse commonly used in studies of insulin
sensitivity. The original strain employed for the global GSK-3a
knockout [11] was an out-bred strain termed ICR. The tissue-
specific knockouts of GSK-3b were initially reported [12] on the
C57Black/6 in-bred strain (hereafter termed C57BL/6). In
addition, tissue-specific Cre animals were on mixed C57BL/6
and 129 (both in-bred) background. Here, we report that on the
C57BL/6 strain, skeletal muscle deletion of GSK-3a does not
result in increased insulin sensitivity. Similarly and unexpectedly,
the liver-specific GSK-3a KO also lacks obvious sensitization
towards insulin or glucose. These observations led us to examine
whether there are strain-specific effects associated with the ability
of GSK-3a to regulate glucose metabolism. We conclude that the
anti-diabetic phenotype observed in the global GSK-3a KO
animals is not a result of a direct effect of inactivation of GSK-3a
in either the muscle or liver and is strain-dependent.
Materials and Methods
Ethics Statement
The animal experimentation conducted during this study was
performed under the guidance and approval of the Toronto
Centre for Phenogenomics (TCP) animal care committee under
protocol #0047a-H. This protocol minimized any suffering for the
mice used through use of analgesics where appropriate. All
procedures were subject to regular external evaluation by the
Canadian Council for Animal Care.
Mouse strains
The GSK-3a floxed and the GSK-3a global knockout mice
were generated as previously described [11]. The global deletions
of exon 2 of GSK-3a were bred onto both the ICR and C57BL/6
backgrounds whereas the GSK-3a floxed animals were generated
on a C57BL/6 background only (most breedings exceeded 6 back-
crosses to ensure strain purity and employed heterozygous animals
and genotyping). Skeletal-muscle specific GSK-3a knockout
animals were generated by breeding the conditionally targeted
GSK-3a floxed mice with mice expressing Cre under the control
of the myosin light chain 1f (MLC1f) promoter (kindly provided by
Steve Burden, Skirball Institute, NY as previously described
[12,14]. These GSK-3a flx/flx MLC1f-cre + mice (C57BL/6/129
background: F5 Backcross) are denoted MLC Cre +. To generate
liver-specific GSK-3a knockout animals, the GSK-3a floxed mice
were crossed to the C57BL/6 Cg-Tg(Alb-Cre)21Mgn/J (JAX lab)
strain which carries Cre recombinase under the control of the
albumin promoter as previously described [12,15]. These GSK-3a
flx/flx AlbCre + mice (C57BL/6/129 background: F5 backcross)
are designated Alb Cre +. Genotypes for the various tissue-specific
deletions were confirmed by PCR for the presence of Cre and for
the detection of the deleted, floxed GSK-3a allele. The GSK-3a
flx/flx lines demonstrated similar expression of GSK-3 protein as
well as other components of the insulin-signaling pathway when
compared to wild type (WT) animals (data not shown). We
performed additional experiments to demonstrate that the
presence of the Alb-Cre or MLC-Cre transgene in animals wild
type with respect to GSK-3 had no significant effects on the
metabolic profiles (as assessed by glucose tolerance (GTT) and
insulin tolerance tests (ITT)) analyzed in these studies (data not
shown). In addition, all studies were performed with respective
littermate controls to control for possible environmental influences.
Male animals were housed 5 per cage under a light/dark cycle
of 12 hours each, in the Toronto Centre for Phenogenomics
(TCP) animal facility, with free access to food and water except
where noted. Individual body weights were monitored over a 22-
week period. For confirmation of genotypes, genomic DNA
prepared from tail snips was analyzed by PCR.
Glucose and Insulin Tolerance Test
Mice were fasted overnight (16–18 h) and administered 2 mg/g
glucose by intraperitoneal injection (i.p.) for glucose tolerance
testing and fasted for 5 h prior to i.p. injection of 1 mU/g insulin
for insulin tolerance testing. Blood glucose was assayed from the
tail vein using the OneTouch UltraSmart blood glucose
monitoring system (Lifescan, Canada) at the indicated times.
Plasma Insulin ELISA
Blood was collected from the tail vein of random-fed mice, or
following an overnight (16–18 h) fast. Plasma was assayed for
insulin using a rat/mouse insulin enzyme-linked immunosorbent
assay kit (ALPCO diagnostics).
Preparation of Tissue Lysates
Mice were fasted overnight and either treated with 150 mU/g
insulin or 2 mg/g glucose for 15 min by i.p. injection. Following
experimental manipulation, tissues were extracted and lysed in lysis
buffer (150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 1 mM
EDTA, 50 mM Tris, pH 8.0, 10 mM NaF, 1 mM Na-orthovana-
date, 10 mM b-glycerophosphate and one ‘Complete’ protease
inhibitor cocktail tablet/50 ml) using a 2 ml Kontes
TM Tissue
grinder. Lysates were centrifuged (16,000 g,4 uC for 15 min) and
protein concentration determined by Biorad DC protein assay.
Immunoblotting
Tissue lysates (20 mg) were subjected to SDS-PAGE and
proteins transferred onto PVDF membrane. Membranes were
blocked for 1 h at room temperature in 5% non-fat milk/Tris-
buffered saline (50 mM Tris-HCl, 150 mM NaCl, pH 7.4)
containing 0.1% Tween-20 prior to probing with antibodies
directed against the following antigens: GSK-3a/b (1:10,000,
Biosource), phospho-GSK-3b (1:1000, Cell Signaling), b-catenin
(1:1000, BD Transduction Laboratories), PKB (1:1000, Cell
Signaling), phospho-PKB Ser
473 (1:1000, Cell Signaling Technol-
ogies), GS (GYS1, 1:1000, Chemicon), GS (GYS2, 1:1000, gift
from J. Guinovart, University of Barcelona), phospho-GS (1:1000,
Cell Signaling Technologies), b-actin (1:20,000, Abcam), GAPDH
(1:100,000, Abcam), overnight at 4uC. Membranes were washed 3
times in Tris-buffered saline/0.1% Tween-20 prior to incubation
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(1:10,000) antibodies. Visualization was performed using en-
hanced chemiluminescence reagent exposure to Kodak autora-
diographic film. Densitometry quantification was carried out using
an Alpha Innotech FluorChem HD2.
Glycogen Synthase Activity Assay
Frozen skeletal muscle and liver tissue was minced using 1 ml
homogenization buffer (50 mM Tris pH 7.8, 100 mM NaF, 10 mM
EDTA, 5% glycerol and protease inhibitor cocktail tablet) and
homogenized using a Brinkman Polytron. The tissue homogenates
were cleared by centrifugation at 3,000 g for 10 min at 4uCa n d
glycogensynthaseactivitywasassayedfromthesupernatantsaccording
to the method of Thomas et al. [16] based on the incorporation of
uridine 5-diphosphate (
3H) glucose (UDPG) into glycogen.
Glycogen Content
25 mg of muscle or liver tissue was acid hydrolyzed in 2 N HCl
by heating it at 95uC for 2 h and neutralized using 2 N NaOH.
The liberated free-glycosyl units were assayed spectrophotomet-
rically by using a glucose reagent hexokinase-dependent-assay kit
(Amresco, OH) as previously described (4). Glycogen was also
visualized in paraffin-embedded tissue sections by using a periodic
acid-Schiff (PAS) staining kit (Sigma Aldrich). Tissue sections were
also stained with standard hematoxylin and eosin for general cell
morphology.
Figure 1. GSK-3 expression, body weight, plasma insulin concentration, glucose tolerance and insulin sensitivity in C57BL/6/129
GSK-3a muscle KO animals. (A)Brain,heart, liver, testes andquad, gastroc, soleus andEDLmuscles and(B)brain,heart, testes, liver andgastroc from
eight week old MLC Cre 2 (2) and MLC Cre + (+) littermate control animals were extracted and lysed as described in Experimental Procedures and
proteins resolved by SDS-PAGE. Proteins were detected by immunoblotting with antibodies against GSK-3a/b. Even loading was determined using
antibodies toGAPDH. Blots arerepresentativefrom threeseparateexperiments. (B)Body weightof male MLCCre2 (opensquares)andMLCCre + (filled
squares) littermate control mice was monitored weekly from age 4 to 22 weeks. Values are the mean 6 SEM from eight separate animals. (C) Plasma
insulin concentration was determined in eight week old male MLC Cre 2 (open bars) and MLC Cre + (filled bars) littermate control animals under fasted
and fed conditions. Values are the mean 6 SEM from at least seven separate animals. Blood glucose concentration in eight week old male MLC Cre 2
(open squares) and MLC Cre + (filled squares) littermate control mice was measured at the indicated times following administration of (D) 2 mg/g
glucose or (E) 1 mU/g insulin by i.p. injectionas described in Experimental Procedures. Values are the mean 6 SEM from at least seven separate animals.
doi:10.1371/journal.pone.0015845.g001
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Assays of GSK-3 were performed on mouse tissues extracts as
described previously [12]. Briefly, 100 mg of muscle or liver tissue
was lysed in 3 ml of detergent-free lysis buffer (50 mM Tris-HCl,
4 mM EDTA, 2 mM EGTA, 10 mM Nab-glycerophosphate,
5 mM NaF, 1 mM PMSF, 1 mM Na-orthovanadate, protease and
phosphatase inhibitor cocktails, pH 7) and homogenised using a
2 ml Kontes
TM Tissue grinder. The tissue homogenate were
centrifuged at 4,000 g for 30 min at 4uC and the supernatant
applied to a CM-Sepharose fast flow resin column (Amersham)
Figure 2. Effect of GSK-3a muscle KO on insulin signaling. (A) Quad, (B) gastroc and (C) liver from eight week old MLC Cre 2 (2) and MLC Cre
+ (+) littermate control animals was extracted following either an over night (16–18 h) fast alone or an overnight fast followed by i.p. administration
of 150 mU/g insulin for 15 min. Twenty mg of the protein lysate was resolved by SDS-PAGE. Proteins were detected by immunoblotting with
antibodies against phospho-PKB (pSer473), PKB, phospho-GSK-3b (pSer9), GSK-3b, phospho-GS (pSer641) and GS (lower left inset in C). Loading was
determined using antibodies to either GAPDH or b-actin. Blots are representative from five separate experiments. (D) GSK-3 kinase activity was
determined from muscle tissue extracted from male MLC Cre 2 control (open bars) and MLC Cre + (filled bars) mice as described in experimental
procedures. GSK-3 kinase activity was determined using a quantitative peptide phosphorylation assay. GSK-3 kinase activity is expressed relative to
the MLC Cre- control (which is set at 100%) and is the mean 6 SEM of four different muscle samples with each assayed in triplicate. Genetic
background was C57BL/6/129.
doi:10.1371/journal.pone.0015845.g002
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EGTA, 10 mM Nab-glycerophosphate, 2.5% glycerol, 5 mM
NaF, 1 mM PMSF, 1 mM orthovanadate, protease and phospha-
tase inhibitors cocktail, pH 7 (buffer A). The column was washed
with 5 column volumes of low-salt wash buffer (buffer A +20 mM
NaCl) and GSK-3 eluted using buffer A +250 mM NaCl.
Fractions containing the highest concentrations of protein were
pooled and used in a kinase assay to assess GSK-3 activity as
described in [17].
Statistical Analysis
For multiple comparisons statistical analysis was performed
using either two way analysis of variance (ANOVA) followed by a
Bonferroni post test or unpaired student’s t-tests. Data analysis was
performed using GraphPad Prism software and considered
statistically significant at P values ,0.05, unless otherwise stated.
Results
Conditional GSK-3a mice that express a modified allele of
GSK-3a, where exon 2 is flanked by LoxP sequences, have been
previously described [11]. Skeletal muscle-specific GSK-3a
knockout (KO) animals were generated by breeding GSK-3a
floxed mice (flx/flx –C57BL/6/129 background) with mice
expressing Cre under the control of the myosin light chain 1f
(MLC1f) promoter (MLC Cre- C57BL/6B6/129 background), a
gene that is predominantly expressed in fast twitch skeletal muscle
fibres. The resultant skeletal muscle GSK-3a KO mice (MLC Cre
+) are viable, fertile and born to the expected Mendelian
frequency. As expected, GSK-3a expression is completely lost in
quadricep (quad), gastrocnemius (gastroc) and extensor digitorum
longus (EDL) muscles, whereas there is only partial reduction of
GSK-3a expression in soleus, which is primarily composed of slow
twitch fibres (Figure 1A). Importantly in the GSK-3a flx/flx MLC
Cre + (MLC Cre +) mice, loss of GSK-3a expression is restricted
to skeletal muscle tissue only and remains unaltered in brain,
heart, liver and testes of mice when compared to GSK-3a flx/flx
MLC Cre - (MLC Cre -) (Figure 1A). Weekly weight analysis from
age 4–22 weeks revealed no significant differences in whole body
weight between MLC Cre + and MLC Cre - littermate control
animals (Figure 1B).
To determine whether muscle-specific loss of GSK-3a expres-
sion alters whole body metabolism, the concentration of plasma
insulin, glucose tolerance and insulin sensitivity were determined.
Fasted and random fed plasma insulin concentrations were
comparable between MLC Cre + and MLC Cre - littermate
control animals (Figure 1C). Furthermore, both glucose tolerance
and insulin sensitivity showed no significant differences in 8 week
(or 6 month (data not shown)) old male MLC Cre + and MLC Cre
- littermate control mice (Figures 1D and 1E, respectively)
demonstrating that the muscle-specific inactivation of GSK-3a
has minimal effects on glucose tolerance and insulin sensitivity.
Since GSK-3 is a key component of the insulin-signaling
pathway, we assessed whether muscle-specific loss of GSK-3a
Figure 3. Glycogen synthase activity in quad, gastroc and liver of GSK-3a muscle KO animals. Glycogen synthase activity was determined
in (A) quad, (B) gastroc and (C) liver of eight weeks old MLC Cre – (open bars) and MLC Cre + (filled bars) tissues by assaying incorporation of glucose
from uridine diphospho-{6-
3H)-D-glucose into glycogen and expressed as a ratio of activity in the absence divided by that in the presence of glucose-
6-phosphate. Values are the mean 6 SEM for at least five experiments carried out in duplicate. Glycogen content was measured in (D) quad, (E)
gastroc and (F) liver from eight week old MLC Cre 2 (open bars) and MLC Cre + (filled bars) following either an overnight fast or random feeding.
Tissues were extracted, acid-hydrolyzed and glycosyl units assayed using a glucose reagent hexokinase method (Amresco, Ohio) as described in
Experimental Procedures. Glycogen content is expressed as mmol glucose/g tissue. Values are mean 6 SEM from at least five separate animals with
each assayed in triplicate. Genetic background of the animals was C57BL/6/129.
doi:10.1371/journal.pone.0015845.g003
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animals. Tissue extracts were prepared from eight wk old male mice of the genotypes indicated and immunoblotted with antibodies against (A)
GSK-3a/b. Even loading was determined using antibodies to GAPDH. Blots are representative from three separate experiments. (B) Body weight of
male Alb Cre 2 (open squares) and Alb Cre + (filled squares) littermate control mice was monitored weekly from age 4 to 22 weeks. Values are the
mean 6 SEM from nine separate animals. (C) Plasma insulin concentration was determined in eight week old male Alb Cre 2 (open bars) and Alb Cre
+ (filled bars) littermate control animals under fasted and fed conditions. Values are the mean 6 SEM from at least seven separate animals. Blood
glucose concentration in eight week old male Alb Cre 2 (open squares) and Alb Cre + (filled squares) littermate control mice was measured at the
indicated times following administration of (D) 2 mg/g glucose or (E) 1 mU/g insulin by i.p. injection as described in Experimental Procedures. Values
are the mean 6 SEM from fourteen separate animals for Alb Cre – and nine separate animals for Alb Cre +. Genetic background was C57BL/6/129.
doi:10.1371/journal.pone.0015845.g004
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a significant increase in PKB/Akt and GSK-3b phosphorylation.
Muscle-specific loss of GSK-3a did not alter fasted or insulin-
stimulated PKB or GSK-3b phosphorylation status or total
expression of either protein in skeletal muscle tissues (Figures 2A
and 2B, respectively). Assay of GSK-3 activity from MLC Cre +
skeletal muscle extracts revealed a 50% reduction in kinase activity
compared to MLC Cre – control animals (Figure 2C).
GS is dephosphorylated and activated in response to an insulin
signal in muscle and to a glucose-signal in the liver [18]. However,
fasted and insulin- or glucose-induced GS dephosphorylation in
muscle or liver respectively is comparable between MLC Cre +
and MLC Cre - tissues (Figure 2). Furthermore, in line with the
phosphorylation status, fasted and insulin-stimulated GS activity is
similar in quad and gastroc tissues of MLC Cre + compared to
MLC Cre - animals (Figures 3A and 3B). As expected, fasted and
glucose-induced activation of hepatic GS is also comparable
between MCL Cre + and MLC Cre – mice (Figure 3C). In
agreement with these data, we found no significant difference in
the amount glycogen deposited in muscle or liver under fasted or
fed conditions (Figures 3D–F). Together, these data support the
conclusion that the selective inactivation of GSK-3a in skeletal
muscle tissue has little impact on whole body glucose tolerance and
insulin sensitivity.
We previously reported that mice that lack GSK-3a in all tissues
(global KO) display improved whole body glucose and insulin
tolerance and enhanced hepatic glycogen storage and insulin
signaling [11]. To determine whether this effect is manifested by
the action of GSK-3a in the liver, hepatocyte-specific GSK-3a
KO animals were generated by crossing the GSK-3a floxed
Figure 5. Effect of GSK-3a liver KO on insulin signaling. (A) liver, (B) muscle from eight week old Alb Cre 2 (2) and Alb Cre + (+) littermate
control animals were extracted following either an overnight (16–18 h) fast alone or an overnight fast followed by i.p. administration of 150 mU/g
insulin for 15 min. Twenty mg of the protein lysates was resolved by SDS-PAGE. Proteins were detected by immunoblotting with antibodies against
phospho-PKB, PKB, phospho-GSK-3b, GSK-3b, phospho-GS and GS. Even loading was determined by blotting for either b-actin or GAPDH. Blots are
representative from 4 separate experiments. (C) GSK-3 kinase activity was determined from liver tissue extracted from male Alb Cre 2 control (open
bars) and Alb Cre + (filled bars) mice as described in experimental procedures. GSK-3 kinase activity was determined using a quantitative peptide
phosphorylation assay. GSK-3 kinase activity is expressed relative to the Cre2 control (which is set at 100%) and is the mean 6 SEM of four different
liver samples with each assayed in triplicate. Genetic background was C57BL/6/129.
doi:10.1371/journal.pone.0015845.g005
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Cre under the control of the albumin promoter (C57BL/6
background). Like the global GSK-3 KO mice, the hepatocyte-
specific deleted mice (Alb Cre +) are viable, fertile and born to
expected frequency. In the Alb Cre + mice, GSK-3a expression is
selectively lost in liver but remains equivalent in other tissues when
compared to the Alb Cre- control animals (Figure 4A). Further-
more, Alb Cre + mice display similar body weights compared to
their Alb Cre – counterparts (Figure 4B).
The metabolic phenotype of the hepatocyte-specific GSKa KO
was analysed. Measurement of plasma insulin concentration under
fasted and random fed conditions revealed no significant
differences between 8 week old male Alb Cre + and Alb Cre-
control mice (Figure 4C). Interestingly, unlike the global GSK-3a
KO, hepatocyte-specific deletion of GSK-3a revealed no statisti-
cally significant differences in the rate of glucose clearance upon
i.p. administration of glucose or insulin (Figure 4D and 4E
respectively) at 6 months (data not shown). Furthermore, analysis
of insulin signaling in the Alb Cre + mice revealed no differences
in the activation status of the insulin-regulated proteins PKB,
GSK-3 and GS. Indeed, the level of insulin-induced phosphory-
lation of PKB and GSK-3 was similar in liver and muscle tissues of
both Alb Cre + and Alb Cre – mice (figure 5A and 5B
respectively). Assay of GSK-3 activity from Alb Cre + liver
extracts revealed a 50% reduction in kinase activity compared to
Alb Cre – control animals (figure 5C). In addition, the extent of
insulin- and glucose-induced dephosphorylation and activation of
GS in muscle and liver tissues was comparable in Alb Cre + and
Alb Cre – mice (Figures 6A and 6B) and the amount of glycogen
deposited within in these tissues was also unaffected by the loss of
hepatic GSK-3a (Figures 6C and 6D).
Since there was a lack of insulin-sensitization in the tissue-
specific deletions of GSK-3a on the C57BL/6/129 background,
we next questioned whether a ‘‘true bred’’ C57BL/6-GSK-3a
global KO mouse could reproduce the improved metabolic
phenotype observed on the previously reported ICR background
[11]. Interestingly, unlike GSK-3a KO mice on the ICR genetic
background, we observed that animals with a global deletion of
GSK-3a on a C57BL/6 background did not exhibit improved
rates of glucose clearance upon i.p administration of glucose or
insulin (Figure 7A and 7B). This result indicated that there might
be strain-specific effects of GSK-3 deletion in glucose metabolism.
Therefore, to further dissect the mechanism by which the ICR-
GSK-3a KO provoked enhanced insulin sensitivity and hepatic
glucose metabolism, tissue-specific deletions of GSK-3a were
generated on the ICR background. To achieve this, the C57BL/
6/129 GSK-3a floxed mice were backcrossed for 5 generations
onto the ICR background. Since the ICR-GSK-3a global KO
mouse exhibited enhanced glycogen accumulation in the liver
[11], we backcrossed the C57BL/6/129 GSK-3a Alb Cre + tissue
deletor strain onto the ICR background. Similar to C57BL/6/129
global knockout of GSK-3a, the ICR-GSK-3a Alb Cre + animals
did not display any significant differences in the rate of glucose
clearance upon i.p administration of glucose or insulin compared
to the ICR-GSK-3a Alb Cre - littermate controls (Figure 7C and
7D respectively). Furthermore, there was no significant difference
Figure 6. Glycogen synthase activity and glycogen content in muscle and liver of GSK-3 liver KO animals. Glycogen synthase activity
was determined in (A) liver and (B) quad of eight weeks old Alb Cre – (open bars) and Alb Cre + (filled bars) tissues by assaying incorporation of
glucose from uridine diphospho-(6-
3H)-D-glucose into glycogen and expressed as a ratio of activity in the absence divided by that in the presence of
G-6-P. Values are the mean 6 SEM for four separate experiments with each assayed in duplicate. Glycogen content was measured in liver (C) and
quad (D) liver from eight week old ALB Cre 2 (open bars) and ALB Cre + (filled bars) following either an overnight fast or random feeding. Values are
mean 6 SEM from eight separate animals with each assayed in triplicate. For these experiments, the mouse background strain was C57BL/6/129.
doi:10.1371/journal.pone.0015845.g006
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or muscle (data not shown) under fasted or fed conditions.
Discussion
Previous data have demonstrated a beneficial role of acute
GSK-3 inhibition in the treatment of diabetes and obesity.
Treatment of diabetic human skeletal muscle cultures with GSK-3
inhibitors stimulates glycogen synthase activity and potentiates
insulin-stimulated glucose transport and glycogen accumulation
[3]. Moreover, administration of these compounds to diabetic
rodents improves glucose tolerance by increasing hepatic glycogen
synthesis and coordinately reducing glucose output by inhibiting
gluconeogenesis [19]. Whilst GSK-3 inhibitors are unable to
discriminate between GSK-3a and GSK-3b, we and others have
shown that there are indeed isoform- and tissue-specific roles for
GSK-3 in the regulation of glucose metabolism. Selective loss of
GSK-3b in skeletal muscle improves glucose tolerance and insulin
signaling, while removal of this isoform in b-islet cells can reduce
hyperglycaemia in diabetic IRS-2 KO mice [12,13]. Furthermore,
genetic ablation of GSK-3a results in improved whole-body
glucose tolerance that is accompanied with enhanced hepatic
insulin signaling and elevated glycogen accumulation [11]. These
observations led us to investigate which tissues are responsible for
the phenotype observed in the GSK-3a global KO mouse. In the
present study we found that mice harbouring specific deletion of
GSK-3a in skeletal muscle or liver displayed normal sensitivity to
insulin and normal insulin signaling. This unexpected result led us
to initially infer that removal of hepatic GSK-3a is insufficient to
reproduce the whole body improvement of glucose metabolism
that is observed with the global GSK-3a KO mouse. However, we
noted that the characterization of the global GSK-3a KO had
been performed on the out-bred strain, ICR but our tissue-specific
knockout models were on the C57BL/6 in-bred strain (with some
129 strain content from the deletor strains). To test for possible
effects of genetic background, we back-crossed the global GSK-3a
KO onto the C57BL/6/129 background. Unlike the ICR strain,
we observed that global inactivation of GSK-3a on the C57BL/6/
129 background did not result in improved glucose/insulin
tolerance or enhanced hepatic glycogen accumulation (Figure 7)
Figure 7. Glucose tolerance and insulin sensitivity in C57BL/6-GSK-3a global and ICR-GSK-3a liver KO animals. Blood glucose
concentration in eight week old male WT - (open squares) and C57BL/6-GSK-3a KO (filled squares) mice was measured at the indicated times
following administration of (A) 2 mg/g glucose or (B) 1 mU/g insulin by i.p. injection as described in Experimental Procedures. Values are the mean 6
SEM from at least seven separate animals. Blood glucose concentration in eight week old male ICR-GSK-3a Alb Cre 2 (open squares) and ICR-GSK-3a
Alb Cre + (filled squares) littermate control mice was measured at the indicated times following administration of (C) 2 mg/g glucose or (D) 1 mU/g
insulin by i.p. injection as described in Experimental Procedures. Values are the mean 6 SEM from nine separate animals for Alb Cre 2 and ten
separate animals for Alb Cre +. Glycogen content was measured in liver (E) from ICR-GSK-3a Alb Cre 2 (open squares) and ICR-GSK-3a Alb Cre + (filled
squares) following either an overnight fast or random feeding. Values are mean 6 SEM from at least five separate animals with each assayed in
triplicate.
doi:10.1371/journal.pone.0015845.g007
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specific effects of genetic ablation of GSK-3a on glucose
metabolism and led us to generate tissue-specific deletions of
GSK-3a on the ICR background. We speculated that hepatic
deletion of GSK-3a on the ICR background would reproduce the
liver-specific phenotype of the ICR-GSK-3a global KO. However,
this was not found to be the case, as the ICR-GSK-3a Alb Cre +
mice displayed relatively normal insulin sensitivity. These
experiments demonstrate that the role of GSK-3a on glucose
metabolism is complex and is sensitive to genetic background
(through as yet unidentified modifiers) and depends on tissues
other than, or in addition to, skeletal muscle and liver. There are
numerous examples demonstrating that background strain as well
as environmental factors can affect the metabolic phenotypes seen
in transgenic mouse models. For instance, mice that lack IRS-2
exhibit mild to severe diabetes dependent on the background
strain, whereas mice lacking the muscle glycogen subunit of
protein phosphatase 1 (GM) can result in obesity and insulin
resistance in a 129/Ola donor strain, but remain lean and glucose
tolerant in a 129/SvJ background. In the present case, we find that
GSK-3a-induced improvement of whole-body glucose tolerance
and hepatic insulin sensitivity is apparent only within the out-bred
ICR strain and not within the in-bred C57BL/6 strain. It has been
reported that compared to the C57BL/6, the ICR strain is more
susceptible to experimental forms of insulin resistance [20]. We
speculate that the beneficial effect of GSK-3a inhibition is
associated with the genetic/environmental susceptibility of insulin
resistance within these rodent strains. Given the beneficial effects
of GSK-3 inhibitors in obese and insulin resistant rodents [4,6,7],
it would be interesting to determine the effects of GSK-3a KO on
these models.
The current study inducates that the skeletal muscle and liver
tissues are unlikely to be primary contributors to the major
metabolic phenotype observed within the global GSK-3a KO
mice on the ICR background. The tissues responsible for the
improved glucose tolerance and enhanced hepatic insulin signaling
are currently unknown. There is accumulating evidence in rodents
that neuronal insulin signaling plays a significant role in the
maintenance of whole–body glucose homeostasis and also that it
can impinge on metabolic responsiveness to insulin in peripheral
tissues [21]. Indeed, it has been shown that neuronal and
pancreatic deletion of IRS-2 can independently, and co-opera-
tively, function to display many of the metabolic phenotypes
observed in the global IRS-2 null mice [22,23,24]. Interestingly,
there are reports suggesting that hypothalamic insulin signaling
contributes to the regulation of hepatic glucose production
[25,26,27]. Intra-cerebral ventricular (ICV) infusion of insulin
results in the inhibition of glucose production as well as of the
expression of gluconeogenic genes in the liver, independently of
circulating insulin and other glucoregulatory hormones [26].
Thus, based on these findings and considering the lack of effect of
hepatic deletion of GSK-3a reported here, we postulate that
enhanced neuronal insulin signaling may contribute to the
improved metabolic and liver-specific phenotype observed in the
global GSK-3a KO on the ICR background. Indeed, we
previously reported that these mice are leaner and exhibit reduced
levels of circulating leptin [11]. Since neuronal pathways also
influence these parameters, this provides some support for our
hypothesis for a role of GSK-3a within the brain that governs
whole-body metabolism and impinges on hepatic function.
Indeed, we are currently exploring the functional impact of
neuronal GSK-3a in the global KOs by examining insulin and
leptin signaling within specific brain regions (e.g. hypothalamus).
In summary, we demonstrate that genetic background plays an
important role in modulating the effect of inactivation of GSK-3a
on insulin responsiveness and that mice harbouring tissue-specific
inactivation of GSK-3a in skeletal muscle and liver tissues display
normal insulin sensitivity. These findings contrast with the strain-
specific improvement of glucose and insulin sensitivity that occurs
in GSK-3a KO mice on the ICR genetic background, indicating
that other, unknown tissues contribute towards this phenotype.
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